Log in or register to see all Alerts
New HTA Decisions in England
May 2021
Drug name
IMBRUVICA® (ibrutinib)
Company
Janssen
Decision date
//
Therapeutic area
Blood and immune system conditions
Therapeutic sub area
Blood and bone marrow cancers
Decision
Not recommended
Indication
Ibrutinib (Imbruvica) with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma in adults.
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on ibrutinib (Imbruvica) with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma in adults because the company did not provide an evidence submission. Janssen has confirmed that it does not intend to make an evidence submission for the appraisal because it considers that the technology is unlikely to be a cost-effective use of NHS resources. NICE will review this decision if the company decides to make a submission.